SeaStar Medical Announces Late-Breaking Presentation at ASN Kidney Week 2026
Key Highlights
- ➤Late-breaking SAVE Registry data presentation accepted for ASN Kidney Week 2026
- ➤Presentation evaluates pediatric sepsis-associated AKI outcomes versus a historical cohort
- ➤QUELIMMUNE (SCD-PED) received FDA approval in 2024 for life-threatening pediatric AKI
- ➤NEUTRALIZE-AKI pivotal trial underway in adults with AKI requiring continuous renal replacement therapy
DENVER, Oct. 02, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life announced today that a late-breaking abstract evaluating the results of the post-approval SAVE Registry data has been accepted for a special late-breaker poster presentation at the upcoming American Society of Nephrology (ASN) Kidney Week 2026 meeting, taking place in Denver, CO, October 21 – 25, 2026.
Title: Improved Outcomes in Pediatric Sepsis-Associated (SA) AKI: Comparison of the Selective Cytopheretic Device for Pediatrics (SCD-PED) Surveillance Registry (SAVE) with a Historical Cohort
Get started
Create a free account to read the full story.